Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032

Overview

The Europe Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 664.59 USD Billion by 2032 and is projected to grow at a CAGR of 14.28% from 2025 to 2032.

Revenue, 2024 (USD Billion)

330.14

Forecast, 2032 (USD Billion)

664.59

CAGR, 2024 - 2032

14.28%

Report Coverage

Europe

Europe Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion

Europe Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)

Market Growth and Projections:

Market Size (2024): 330.14 USD Billion
Projected Market Size (2032): 664.59 USD Billion
CAGR (2025-2032): 14.28%

Key Findings of Europe Pharmacogenetic Testing in Psychiatry depression Market

The Europe Pharmacogenetic Testing in Psychiatry depression Market was valued at 330.14 USD Billion in 2024.
The Europe Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 14.28% during the forecast period of 2024 to 2032.
In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 247.84 USD Billion
The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 19.61% during the forecast period from 2024 to 2032.

Europe Pharmacogenetic Testing in Psychiatry depression Market Scope

Europe Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope

Genes

COMT
MTHFR
SLC6A4
CYP3A4
HLA-A
HTR2A/C
HLA-B
Others
CYP2D6
CYP2C9 AND VKORC1
CYP2C19

Type

Array-Based Tests
Whole Genome Sequencing

Distribution Channel

Direct-To-Customer Services
Mail-Order Pharmacies
Hospital Pharmacies
Retail Pharmacies

End User

Others
Research Centres And Academic Institutes
Healthcare Providers
Pharmaceutical & Biotechnology Companies

Application

Clinical Practice
Drug Development

Sample

Blood
Saliva

Drug Type

Vitamins/Nutraceuticals
Recreational Drugs
Over-The-Counter Medications
Prescription Drugs

Europe Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights

Study Period	2024-2032
Base Year	2020
Unit	Revenue in USD Billion
Market Value in 2024	330.14 USD Billion
Market Value in 2032	664.59 USD Billion
CAGR (2025-2032)	14.28%
Historic Data	2016-2023
Market Segments Covered	Genes,Type,Distribution Channel,End User,Application,Sample,Drug Type

Regional Insights:

Leading Market (2024-2032): Europe, leading in terms of revenue 330.14 USD Billion in 2024
- Key Country: U.K., leading in terms of revenue with value of 76.41 USD Billion in 2024.

Segments and Scope

Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
- CYP2C19 is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 78.66 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 19.61 % in forecast period 2025-2032.
Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 202.55 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.85 % in forecast period 2025-2032.
Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
- Retail Pharmacies is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 142.52 USD Billion in the year 2024.
- Retail Pharmacies is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.77 % in forecast period 2025-2032.
Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
- Pharmaceutical & Biotechnology Companies is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 149.84 USD Billion in the year 2024.
- Pharmaceutical & Biotechnology Companies is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 15.54 % in forecast period 2025-2032.
Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
- Drug Development is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 179.87 USD Billion in the year 2024.
- Drug Development is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.99 % in forecast period 2025-2032.
Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
- Saliva is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 247.84 USD Billion in the year 2024.
- Saliva is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.62 % in forecast period 2025-2032.
Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
- Prescription Drugs is the largest segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 154.25 USD Billion in the year 2024.
- Recreational Drugs is the Fastest growing segment in Europe Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 14.73 % in forecast period 2025-2032.

Europe Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

Company Name
Millennium Health
Myriad Genetics, Inc.
PerkinElmer Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.

Europe Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

Europe Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

Industry Related Reports

South America Cell And Gene Therapy Thawing Equipment Market

Middle East & Africa Cell And Gene Therapy Thawing Equipment Market

North America Cell And Gene Therapy Thawing Equipment Market

Europe Cell And Gene Therapy Thawing Equipment Market

Asia-Pacific Cell And Gene Therapy Thawing Equipment Market

Argentina Cell And Gene Therapy Thawing Equipment Market

Australia Cell And Gene Therapy Thawing Equipment Market

Belgium Cell And Gene Therapy Thawing Equipment Market

Brazil Cell And Gene Therapy Thawing Equipment Market

Canada Cell And Gene Therapy Thawing Equipment Market

Frequently Asked Questions

What are the primary segments covered in the Europe Pharmacogenetic Testing in Psychiatry depression Market?

The Europe Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Genes,Type,Distribution Channel,End User,Application,Sample,Drug Type.

What is the current market size of the Europe Pharmacogenetic Testing in Psychiatry depression Market?

Europe Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 330.14(Revenue in USD Billion) in 2020.

What is the expected growth rate of the Europe Pharmacogenetic Testing in Psychiatry depression Market?

Europe Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 14.28% during the forecast period of 2024 to 2032.

Which is the dominating segment in the Europe Pharmacogenetic Testing in Psychiatry depression Market?

The Saliva segment is expected to dominate the Europe Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 247.84 USD Billion in 2024